ReviewInfection and drug resistance2019
Omadacycline: a novel aminomethylcycline.
Review in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Resistance of gram-negative and gram-positive pathogens to omadacycline: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Multicenter Real-World Outpatient Use of Intravenous Omadacycline.Infectious diseases and therapy · 2026Article
- Case Report: First In-Human Report of Cure of RefractoryOpen forum infectious diseases · 2026Article
- Article
- A case of severeRespiratory medicine case reports · 2026Article
- Strategic re-engineering of antibiotics.Nature reviews bioengineering · 2025Article
- Omadacycline for the Treatment of SevereInternational medical case reports journal · 2025Article
- A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2025Article
- Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials.Infectious diseases and therapy · 2024Article
- Efficacy of omadacycline in the treatment ofFrontiers in cellular and infection microbiology · 2024Article
- A multi-targeted computational drug discovery approach for repurposing tetracyclines against monkeypox virus.Scientific reports · 2023Article
- Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment.Journal of bone and mineral metabolism · 2023Article
- Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023Review
- Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.EMBO reports · 2023Review
- Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: aFrontiers in medicine · 2023Article
- Case Report: Omadacycline in the treatment of macrolide-unresponsiveFrontiers in cellular and infection microbiology · 2023Article
- Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance.Annals of medicine · 2022Review
- Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.Antimicrobial agents and chemotherapy · 2022Article
- Omadacycline for the Treatment of SevereInfection and drug resistance · 2022Article
- The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tetracyclines have come a long way since they became available almost seven decades ago, with numerous enhancements allowing new agents to overcome bacterial mechanisms of resistance. However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects and poor oral bioavailability seen with the glycylcylcines. Omadacycline, a new and improved tetracycline, has demonstrated a broad spectrum of in vitro activity, has oral and intravenous formulations, improved safety compared to glycylcyclines, as well as clinical efficacy and safety for two types of infections: acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. This review will summarize salient points about its pharmacologic properties, available clinical efficacy, and safety data and omadacycline's place in therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.